期刊文献+

不同剂量三参饮改善干燥及NOD小鼠颌下腺PD-1及PD-L1高表达情况 被引量:2

Clinical effective of different doses of San Shen Yin treatment on Sjogren’s syndrome and improvement of expression of PD-1 and PD-L1 on animal models’ salivary glands
在线阅读 下载PDF
导出
摘要 目的:研究不同剂量三参饮治疗干燥综合征患者疗效,并在干燥综合征动物模型上研究不同剂量三参饮治疗后,其颌下腺PD-1及PD-L1高表达情况。方法:自2013年4月至2018年4月,在我院就诊原发性干燥综合征患者共110例,根据治疗剂量随机分为高剂量组、中剂量组和低剂量组,予以不同剂量的三参饮治疗,观察疗效及不良反应情况。而后,利用不同剂量三参饮喂养干燥综合征模型鼠,免疫组化观察其颌下腺中PD-1及PD-L1表达情况。结果:予以三参饮辅助干燥综合征治疗,可明显改善患者口咽、眼部、鼻腔等部位的干燥症状。同时高剂量组疗效优于低剂量组,组间比较差异有统计学意义。在干燥综合征模型鼠中,予以三参饮灌胃,可降低小鼠颌下腺中PD-1及PD-L1表达,同时高剂量组PD-1及PD-L1表达较中、低剂量组降低明显(P<0.05)。结论:三参饮治疗可明显改善干燥综合征患者临床症状,高剂量治疗效果更佳,此外,三参饮可能通过对免疫细胞调节发挥临床作用。 Objective: To study the clinical effective of different doses of San Shen Yin treatment on the Sjogren′s syndrome and the improvement of the expression of PD-1 and PD-L1 on salivary glands. Methods: From April,2013 to April,2018,110 Sjogren′s Syndrome patients were recruited into the study.They were divided into three groups:High Dose Group,Middle Dose Group and Low Dose Group randomly and accepted different doses of San Shen Yin treatment.Then,patients were followed up and monitor their clinical effective.At the same time,we set up mice model of Sjogren′s Syndrome.These mice were feed by high,middle and low doses San Shen Yin.After that,the expressions of PD-1 and PD-L1 in salivary glands of mice were observed by immunohistochemistry. Results: The San Shen Yin treatment could improve patients′ clinical symptoms of dryness in the oropharynx,eyes,nasal cavity.Compared with the Low Dose Group,patients in the High Dose Group have got better improvement in the clinical effective.The significant difference was found in the different groups patients.In Sjogren′s Syndrome mice,the San Shen Yin treatment reduced the expressions of PD-1 and PD-L1 in salivary glands.The High Dose Group mice had the lowest expressions of PD-1 and PD-L1 ( P <0.05). Conclusion: The San Shen Yin improved the clinical effective in Sjogren′s Syndrome patients,and the higher dose of the San Shen Yin got better improvement of the clinical symptoms.The San Shen Yin might play its role via the modification of the immune system.
作者 陈月月 汪悦 钱冬晨 何静 郭亮 徐媚媚 胡伟 徐蕾 CHEN Yue-Yue;WANG Yue;QIAN Dong-Chen;HE Jing;GUO Liang;XU Mei-Mei;HU Wei;XU Lei(The Third Affiliated Hospital of Nanjing University of Traditional Chinese Medicine,Nanjing 210001,China)
出处 《中国免疫学杂志》 CAS CSCD 北大核心 2019年第10期1193-1198,共6页 Chinese Journal of Immunology
基金 2017南京市计委课题(YKK17152)
关键词 三参饮 干燥综合征 PD-1 PD-L1 San Shen Yin Sjogren′s Syndrome PD-1 PD-L1
  • 相关文献

参考文献7

二级参考文献56

  • 1李贵安,陈爱林,王素芝.中医辨证分型治疗干燥综合征56例[J].陕西中医,2007,28(2):168-169. 被引量:21
  • 2颜淑敏,曾小峰.原发性干燥综合征诊治进展[J].实用医院临床杂志,2007,4(3):6-8. 被引量:23
  • 3Vitali C, Bombardieri S, Jonsson R, eta/. Classification criteria for Sjfigren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group[J]. Ann Rheum Dis, 2002, 61:554-558.
  • 4Keiko M, Masahiro I, Haruki K, et al. The wide spectrum of clinical manifestations in Sjogren's syndrome-associated neuropathy[J]. Brain, 2005, 128:2518-2534.
  • 5LafitteZ C, Amoura P. Neurological complications of primary Sjogren's syndrome[J]. J Neurol, 2001, 248:577-584.
  • 6Daisuke W, Takashi K , Takahisa G, et M. Extreme ettlcacy of intravenous immunoglobulin therapy for severe burning pain in a patient with small fiber neuropathy associated with primary Sjogren's syndrome[J]. Mod Rheumatol, 2009, 19: 437 -440.
  • 7Goransson LG, Herigstad A, Tjensvoll AB, et al. Peripheral neuropathy in primary Sjogren's syndrome.A population- based study[J]. Arch Neurol, 2006, 63:1612-1615.
  • 8董怡.2002年修订的干燥综综合征国际分类(诊断标准)[J].中华风湿病学杂志,2002,6(4):257.
  • 9Moerman RV,Arends S,Meiners PM,etal.EULAR Sjogren's Syndrome Disease Activity Index (ESSDAI) is sensitive to show efficacy of rituximab treatment in a randomised controlled trial[J].Annals of the rheumatic diseases,2014,2(73):472-476.
  • 10Luo Q,Sun Y,Liu W,et al.A novel disease-modifying antirheumatic drug,iguratimod,ameliorates murine arthritis by blocking IL-17 signaling,distinct from methotrexate and leflunomide[J].Journal of immunology (Baltimore,Md:1950)2013,191(10):4969-4978.

共引文献62

同被引文献7

引证文献2

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部